Shots:
The US FDA has approved label expansion of Jaypirca (pirtobrutinib; 100 & 50mg) for the treatment of adults with r/r CLL/SLL who were previously treated with a covalent BTK inhibitor & converted the accelerated approval of Dec 2023 to a full approval
Label expansion was based on the P-III (BRUIN CLL-321) study assessing Jaypirca…
